Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea

Vivos’ stock rose from $4.39 Tuesday to $41 Wednesday, as the clearance positions the company to offer an alternative to continuous positive airway pressure devices and neurostimulation implants.